Boston Medical Center is Leading the Way in Social Impact

 

Boston Medical Center (BMC) is at the forefront of health equity and social impact. Its dedicated focus is on addressing social determinants of health and improving outcomes for underserved communities. This emphasis aligns with current trends in healthcare, where social impact and community engagement are becoming increasingly critical.

In this episode of the “Healthcare Rethink” podcast, host Brian Urban sits down with Sheila Phicil, a Social Innovation Architect at BMC, to discuss the institution’s pioneering health equity and social impact efforts. Phicil shares insights into BMC’s Health Equity Accelerator, a program designed to eliminate health disparities and enhance community well-being through innovative strategies and partnerships.

Phicil recounts her journey from a first-generation Haitian American in Orlando to her current role at BMC. She highlights how her early experiences in leadership and community organizing have shaped her approach to addressing health disparities and driving social impact. Her work involves navigating complex social determinants of health and fostering economic mobility for BMC’s diverse patient population.

At BMC, the Health Equity Accelerator aims to close health disparities by geography, race, and other factors. Phicil explains the program’s history and evolution, emphasizing the need for culturally relevant and humble care. She also discusses the role of navigators in connecting patients with essential resources, such as housing, food, and employment support.

Phicil’s vision for the future includes shifting from a charity-based model to an equity-focused approach, where healthcare institutions leverage their resources to empower communities and promote generational well-being. This holistic strategy involves collaborating with various partners, from local organizations to major institutions, to address the multifaceted needs of the community and amplify their social impact.

 

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…